Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Wednesday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE BTX opened at $1.12 on Wednesday. The company has a 50-day simple moving average of $1.26 and a two-hundred day simple moving average of $1.66. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The firm has a market cap of $65.89 million, a price-to-earnings ratio of -0.49 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.